How Does Pacira Company's Operating Model Create Value?

EXPAREL, based on DepoFoam sustained-release liposome technology, delivers prolonged bupivacaine release for up to 72 hours of postoperative analgesia. Pacira operating model centers commercialization, supply, and clinical evidence generation around this single core product platform.

The solution targets hospitals, ambulatory surgery centers, and anesthesiologists facing high opioid-prescription rates, opioid-related complications, and regulatory pressure such as the NOPAIN Act effective January 1, 2025. Adoption is driven by demand for safer, longer-lasting analgesia that shortens recovery and lowers opioid consumption.

Hospitals choose EXPAREL for fewer opioid-related adverse events, shorter length of stay, and improved patient satisfaction; published studies and real-world evidence support reductions in opioid use by up to 50% in select procedures. Pacira value creation links clinical outcomes to purchasing decisions and hospital formularies.

By focusing on DepoFoam and EXPAREL, Pacira business model concentrates R&D, regulatory, and commercial resources to scale adoption, protect pricing, and maintain manufacturing quality-trading product breadth for depth and defensibility in non-opioid pain management markets.

EXPAREL generated $575.1 million of Pacira BioSciences, Inc.'s $726.4 million total 2025 revenue, making it the primary revenue stream by far; high clinician adoption in surgical settings sustains volume and pricing power. This concentration underpins the Pacira operating model and Pacira value creation.

ZILRETTA contributed $116.6 million and iovera $24.2 million in 2025, providing diversification across orthopedic and outpatient pain markets; licensing, partnerships, and potential services around product training add incremental revenue. See Market Segmentation of Pacira Company for related segmentation context.

Pacira monetizes through unit sales to hospitals and outpatient clinics at premium prices supported by clinical differentiation and reimbursement; favorable Medicare policy shifts (NOPAIN Act) reduce payer friction and protect pricing power. High non – GAAP gross margin of 81% in 2025 converts sales into operating leverage.

The largest driver of value capture is gross margin expansion tied to EXPAREL volume plus intellectual property: Pacira BioSciences, Inc. holds 21 patents, and an April 2025 volume – limited settlement extends EXPAREL exclusivity to 2039, potentially to 2044-this secures long – term pricing and cash flow. Operational efficiencies in manufacturing further improve unit economics.

The model rests on a massive exclusivity window for EXPAREL extending into the 2040s and alignment with the NOPAIN Act, which supports hospital adoption of non-opioid pain management; this creates near-term pricing power and formulary access advantages.

EXPAREL generated the bulk of cash in 2025, supporting $186.5 million Adjusted EBITDA that Pacira uses to fund R&D and geographic expansion, enabling an opportunistic pivot toward gene therapy (PCRX-201) while sustaining operations.

Nearly 80% of 2025 revenue came from EXPAREL, making Pacira highly sensitive to elective surgery volumes; management reported a relatively soft elective market in 2026, increasing downside risk to top-line and cash flow forecasts.

Activist pressure from DOMA Perpetual Capital Management highlights investor skepticism about board oversight and the pace of pipeline diversification; the model's success depends on timely commercialization of PCRX-201 and other programs before legacy decline.